Immunovia (IMMNOV: Nasdaq Stockholm) and the company’s lab director, Dr. Lisa Ford, have been awarded a Distinguished Abstract Award by the Academy of Diagnostics & Laboratory Medicine (ADLM) for the abstract “Validation of a five-biomarker test in serum for detection of early-stage pancreatic ductal adenocarcinoma”.

The Fellows of the ADLM selected 19 abstract winners for the 2025 Distinguished Abstracts Award, recognizing their scientific excellence out of more than 800 abstracts reviewed for the prestigious ADLM 2025 Annual Meeting.

“This recognition of Immunovia’s analytical validation study of the PancreaSure test reflects the rigor, relevance, and impact of our efforts to develop and validate the test. The award recognizes the strong scientific foundation of the PancreaSure test, which should inspire physician confidence in the test," says Lisa Ford, Ph.D., Clinical Laboratory Director at Immunovia.

Immunovia’s Clinical Laboratory Director, Dr. Lisa Ford, will present the awarded abstract during the ADLM 2025 Annual Meeting’s poster session on July 30th. The abstract focuses on the validation of the analytical performance of Immunovia’s PancreaSure test across a comprehensive set of parameters, reinforcing the reliability, precision and robustness of the test.

“The award from ADLM is well-deserved recognition of the fantastic work done by Dr. Lisa Ford and the Immunovia lab team. This is just one example of the rigorous scientific work completed to prepare the PancreaSure test for a successful US launch in September,” says Jeff Borcherding, CEO of Immunovia.

The Association for Diagnostics & Laboratory Medicine is the premier global scientific and medical professional organization dedicated to clinical laboratory science and its application to healthcare. The ADLM helps laboratory professionals provide vital insight and guidance to improve patient access to needed care.

For further information, please contact
Jeff Borcherding, CEO
jeff.borcherding@immunovia.com

Immunovia in brief
Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world’s largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm.
For more information, please visit www.immunovia.com.

Attachments
Immunovia’s Analytical Validation Study Recognized for its Scientific Excellence by the ADLM

Läs mer på MFN